This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

Azithromycin is a 15-membered macrolide antibiotic that has antibacterial effects on a variety of Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. Its mechanism of action is the same as that of erythromycin, mainly binding to the 50S subunit of bacterial ribosomes and inhibiting RNA-dependent protein synthesis.

This product is a diamine oxidase inhibitor, which has a more obvious dilating effect on cerebrovascular and cardiovascular systems, especially on the vertebral artery system, significantly increasing the blood flow of the heart, brain and peripheral circulation, improving blood circulation, and lowering systemic blood pressure. In addition, it can increase the blood flow of the cochlea and anterior base, thereby eliminating inner ear vertigo, tinnitus and ear closure, and can also increase capillary permeability, promote the absorption of extracellular fluid, and eliminate lymphatic edema; it can counteract the vasoconstrictive effect of catecholamines and lower arterial pressure, and has the effect of inhibiting plasma coagulation and ADP-induced platelet aggregation, can prolong the time of thrombosis in vitro in rats, and has a slight diuretic effect.

Oral absorption is slow, 85-90% is absorbed by the small intestine, the absorption rate varies greatly from person to person and is affected by food. Newborns absorb very poorly. Oral bioavailability is about 79%, distributed in intracellular and extracellular fluids, and the intracellular content may be more than the extracellular content, with an apparent distribution volume of 0.6L/kg. The plasma protein binding rate is 88-92%, mainly bound to albumin, and the protein binding in brain tissue may be even higher. The blood concentration reaches its peak 4-12 hours after oral administration. It is mainly metabolized in the liver, and the metabolites are pharmacologically inactive, mainly hydroxyphenytoin (accounting for about 50-70%). This metabolism has genetic polymorphism and racial differences. There is an enterohepatic circulation, which is mainly excreted through the kidneys, and alkaline urine excretion is faster. T1/2 is 7-42 hours. For patients who take phenytoin sodium for a long time, T1/2 can be 15-95 hours, or even longer. After a certain dose of the drug is applied, the liver metabolism (hydroxylation) capacity reaches saturation. At this time, even if the dose is increased by a small amount, the blood concentration increases nonlinearly and sharply, and there is a risk of poisoning. The blood concentration should be monitored. The effective blood concentration is 10~20mg/L. Oral administration of 300mg daily can reach a steady-state concentration in 7~10 days. When the blood concentration exceeds 20mg/L, toxic reactions are likely to occur, such as nystagmus; when it exceeds 30mg/L, ataxia occurs; when it exceeds 40mg/L, serious toxic effects often occur. It can pass through the placenta and can be secreted into breast milk.

Phenothiazine antipsychotics block dopamine receptors (DA2) in the mesolimbic system and mesocortical pathways, and have blocking effects on dopamine (DA1) receptors, 5-hydroxytryptamine receptors, M-type acetylcholine receptors, and α-adrenaline receptors. At low doses, they can inhibit dopamine receptors in the medulla oblongata emetic chemoreceptor area, and at high doses, they can directly inhibit the vomiting center, producing a powerful antiemetic effect. They inhibit the body temperature regulation center, lower body temperature, block the action of peripheral α-adrenaline receptors, dilate blood vessels, cause a drop in blood pressure, and have a certain effect on the endocrine system.